- Open
- 1497.00
- High
- 1540.00
- Low
- 1483.69
- Close
- 1533.00
- Change
- +34.00 (2.27%)
- Volume
- 203,170
| 2 Sept 2026 | 13:45:35 | Holding(s) in Company |
| 1 Sept 2026 | 16:13:04 | Total Voting Rights |
| 28 Aug 2026 | 07:00:01 | Transaction in Own Shares |
| 24 Aug 2026 | 15:03:25 | Director/PDMR Shareholding |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 2 Sept 2026 | 13:45:35 | Holding(s) in Company |
| 1 Sept 2026 | 16:13:04 | Total Voting Rights |
| 28 Aug 2026 | 07:00:01 | Transaction in Own Shares |
| 24 Aug 2026 | 15:03:25 | Director/PDMR Shareholding |
| 18 Mar 2026 | 2025 Annual Report and Accounts | |
| 19 Mar 2025 | 2024 Annual Report and Accounts | |
| 22 Mar 2024 | 2023 Annual Report and Accounts |
Hikma Pharmaceuticals plc is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic, specialty, and branded medications. Its operations are divided into three main segments: Injectables, which supplies hospitals with generic and specialty injectable products; Branded, which offers branded generics and in-licensed patented products primarily in the MENA region; and Hikma Rx, which provides oral and respiratory generic products to the North American retail market. Hikma operates manufacturing facilities and R&D hubs across North America, Europe, and the MENA region, serving healthcare providers and patients in over 50 countries.
| 24 Aug 2026 |
| 10:54:12 |
| Transaction in Own Shares |
| 21 Aug 2026 |
| ii view: Hikma keeps a healthy pulse with solid first half |
| 12 Aug 2026 | Citi sees Hikma discount as unwarranted after upgrade to forecasts |
| 10 Aug 2026 | Hikma boost as broker raises price target |
| 6 Aug 2026 | FTSE 250 round-up: records, Harbour Energy, Hikma Pharma, OSB |
| 6 Aug 2026 | Hikma jumps 10% as brokers point to profit beat and undemanding rating |
| 31 Jul 2026 | Week Ahead: BP, HSBC, L&G, Glencore, Diageo, Persimmon |
| 24 Aug 2026 |
| 10:54:12 |
| Transaction in Own Shares |
| 21 Aug 2026 |
| ii view: Hikma keeps a healthy pulse with solid first half |
| 12 Aug 2026 | Citi sees Hikma discount as unwarranted after upgrade to forecasts |
| 10 Aug 2026 | Hikma boost as broker raises price target |
| 6 Aug 2026 | FTSE 250 round-up: records, Harbour Energy, Hikma Pharma, OSB |
| 6 Aug 2026 | Hikma jumps 10% as brokers point to profit beat and undemanding rating |
| 31 Jul 2026 | Week Ahead: BP, HSBC, L&G, Glencore, Diageo, Persimmon |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.21bn | -0.1% | |
HIKHikma Pharmaceuticals plc | £3.20bn | -0.1% |
| £451m | -0.4% | |
| £317m | -0.4% | |
| £308m | +0.0% | |
| £273m | -0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.21bn | -0.1% | |
HIKHikma Pharmaceuticals plc | £3.20bn | -0.1% |
| £451m | -0.4% | |
| £317m | -0.4% | |
| £308m | +0.0% | |
| £273m | -0.1% |